Browsing by Author "Susanto, Hendra"

Now showing 1 - 5 of 5

Altered plasma acylcarnitine and amino acid profiles in type 2 diabetic kidney disease
(2016-06)
Chuang, Wen-Han
;
Arundhathi, Arivajiagane
;
Lu, Ching
;
Chen, Chang-Chiang
;
Wu, Wan-Chen
Introduction Dysregulation of acylcarnitines (AcylCNs) and amino acids metabolism have implicated in abnormality of fatty acid oxidation in type 2 diabetes (T2D). However, it is not well known whether altered plasma AcylCN, and amino acid profiles are associated with albuminuria or diabetic nephropathy (DN) in T2D. Objective The aim of this study was to elucidate alterations in plasma levels of AcylCNs and amino acids with respect to the T2D patients with various stages of albuminuria. Methods We recruited 52 healthy subjects as control, and 156 T2D patients which were divided into 52 normoalbuminuria, 52 microalbuminuria, and 52 macroalbuminuria. Plasma 37 AcylCNs and 12 amino acids were analyzed by tandem mass spectrometry. Results We found that T2D with normoalbuminuria and microalbuminuria had lower shot-, medium-, and long-chain AcylCNs, whereas T2D with macroalbuminuria had higher short-and medium-chain AcylCNs and lower long-chain AcylCNs than healthy subjects. Moreover, estimated glomerular filtration rate (eGFR) was a negative, independent and significant predictor of albumin to creatinine ratio (ACR) levels (beta = -0.376, P < 0.001), whereas plasma Low-density lipoprotein cholesterol (LDL-C) was significantly and positively associated with ACR levels (beta = 0.169, P = 0.049). Furthermore, multivariate ordinal logistic regression analysis revealed that isobutyrylcarnitine (C4) was a positive, independent, and significant predictor of ACR levels with higher odds of having T2D patients with progression normoalbuminuria to microalbuminuria [OR = 9.93, 95 % CI (3.51-28.05), P < 0.001]. Conclusions The findings suggest that plasma C4 may serve as a potential biomarker for the early stages of DN.
Enhancing Early Stage of Hepatocellular Carcinoma: Does Correlate to MicroRNA 122 and miR196a Interaction?
(2019-01-01)
Susanto, Hendra
;
Wang, Chih-Hong
;
Aulanni'am, Aulanni'am
;
Handaya, Adeodatus Yuda
;
生物科技學系
Hepatocellular carcinoma (HCC) is a representative of almost 85-90% of liver cancer in the recent global incidence. HCC is the second leading cause of mortality in subjects with cancer. The higher prevalence of this disease significantly increased in the Asia Pacific region in the last decades. Fatty liver (steatosis) linked cirrhosis showed a substantial contribution to the acceleration of HCC in patients. Importantly, another primary inducer of fatty liver, a short non-coding RNA miR-122, and miR196a are the essential miRNAs that predicted enhance the progression of HCC in the younger age. However, the lack of information about HCC related liver-derived hormone and miRNA remains. This study was conducted by using miR-122(+/-)-miR-196 (+) to generate miR-122(-/-)-miR 196 (+). In the current data, the significant morphological alteration of the liver with the early formation of nodule-like in the surface area was observed. Based on the histological section, the chronic portal inflammation also occurred in the liver of this double genetic modification mouse model. In summary, the interaction of miR-122 and miR196a may accelerate liver fibrosis due to chronic inflammation within the liver progress to cirrhosis in the early stage of hepatocellular carcinoma.
Higher serum betatrophin level in type 2 diabetes subjects is associated with urinary albumin excretion and renal function
(2016-01-07)
Chen, Chang-Chiang
;
Susanto, Hendra
;
Chuang, Wen-Han
;
Liu, Ta-Yu
;
Wang, Chih-Hong
Background: Betatrophin is a newly identified liver-derived hormone that is associated with glucose homeostasis and lipid metabolism. Although dysregulated lipid metabolism results in diabetic nephropathy (DN) development in patients with type 2 diabetes mellitus (T2DM), it is not understood whether betatrophin is associated with urinary albumin excretion and renal function. Methods: Based on albumin/creatinine ratio (ACR), 109 T2DM patients were divided into normoalbuminuria (ACR < 30 mg/g), microalbuminuria (ACR between 30 and 300 mg/g), and macroalbuminuria (ACR > 300 mg/g). Serum betatrophin levels of 109 T2DM patients and 32 healthy subjects were determined by enzyme-linked immunosorbent assay (ELISA). Results: Serum level of betatrophin was significantly increased in T2DM patients with normoalbuminuria, microalbuminuria, and macroalbuminuria as compared with healthy subjects (P < 0.001). Serum betatrophin level was positively correlated with sex, duration of diabetes, systolic blood pressure (SBP), body mass index (BMI), ACR, and triglyceride, whereas it was inversely correlated with estimated glomerular filtration rate (eGFR), total cholesterol, and high-density lipoprotein cholesterol (HDL-C) (P < 0.001). Furthermore, multivariate regression analysis showed the betatrophin was significantly and positively independent with triglyceride and low-density lipoprotein cholesterol (LDL-C) (P < 0.05), whereas it was inversely independent with eGFR, total cholesterol, and low-density lipoprotein cholesterol (HDL-C) (P < 0.05). In addition, the betatrophin had higher odds of having DN [odds ratio (OR) = 5.65, 95 % confidence interval (CI) 2.17-14.57, P < 0.001]. Conclusion: Betatrophin is significantly increased in T2DM patients with different stages of albuminuria. Betatrophin may be a novel endocrine regulator involved in DN development.
Higher serum betatrophin level in type 2 diabetes subjects is associated with urinary albumin excretion and renal function (vol 15, pg 3, 2016)
(2017-04-26)
Chen, Chang-Chiang
;
Susanto, Hendra
;
Chuang, Wen-Han
;
Liu, Ta-Yu
;
Arundhathi, Arivajiagane
Increased serum levels of betatrophin in pancreatic cancer-associated diabetes
(2016-07-05)
Susanto, Hendra
;
Liu, Ta-Yu
;
Chen, Chang-Chiang
;
Purnomo, Jerry D. T.
;
Chen, Shu-Fan
Long-standing diabetes or glucose intolerance is recognized as a crucial event in the process of pancreatic cancer. Betatrophin, a novel liver-derived hormone, promotes beta-cell proliferation and improves glucose intolerance. However, the relationship between betatrophin and PDAC-associated diabetes is not fully understood. To evaluate the serum betatrophin levels in PDAC-associated diabetes, a total 105 Taiwanese subjects including 15 healthy subjects, and 12 patients having PDAC with normal glucose tolerance (PDAC-NGT), 12 patients having PC with impaired glucose tolerance (PDAC-IGT), and 66 patients having PC with diabetes mellitus (PDAC-DM) were enrolled for this study. Serum betatrophin and carbohydrate antigen 19-9 (CA19-9) levels were analyzed by enzyme-linked immunosorbent assay (ELISA). Compared to healthy subjects, PDAC patients had higher levels of betatrophin and CA19-9. Consistently, betatrophin protein was significantly expressed in pancreatic ductal of PDAC-associated DM patients using immunohistochemistry (IHC) method. Furthermore, multivariate regression analysis showed the betatrophin was significantly and positively independent with T category (beta = 0.605, P=0.010), serum albumin (beta = 0. 423, P=0.021), lipase (beta = 0.292, P=0.039), and blood urea nitrogen (BUN) (beta = 0.303, P=0.040). Further, the betatrophin was three folds of having PDAC-associated diabetes with the highest odds ratio [OR=3.39; 95% CI (1.20-9.57); P=0.021) and receiver operating characteristic (ROC) curve analysis showed that AUC value of betarophin was 0.853 which is slightly larger than AUC value of CA19-9 (0.792) in PDAC-DM patients. Interestingly, AUC value of betarophin plus CA19-9 was 0.988 in PDAC-DM patients. Therefore, betatrophin combined CA19-9 may serve as a potential biomarker for PDAC-associated diabetes.